• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ACTU

    Actuate Therapeutics Inc.

    Subscribe to $ACTU
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year: 2024

    Exchange: NASDAQ

    Recent Analyst Ratings for Actuate Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    4/22/2025$21.00Buy
    Craig Hallum
    3/17/2025$20.00Buy
    H.C. Wainwright
    See more ratings

    Actuate Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Actuate Therapeutics with a new price target

      Craig Hallum initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $21.00

      4/22/25 8:00:39 AM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Actuate Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $20.00

      3/17/25 7:17:09 AM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Actuate Therapeutics Inc. SEC Filings

    See more
    • Actuate Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

      5/6/25 8:09:06 AM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Actuate Therapeutics Inc.

      EFFECT - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

      4/17/25 12:15:10 AM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Actuate Therapeutics Inc.

      424B3 - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

      4/16/25 5:05:21 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form D filed by Actuate Therapeutics Inc.

      D - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

      4/10/25 5:28:44 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Actuate Therapeutics Inc.

      DEFA14A - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

      4/8/25 7:02:27 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Actuate Therapeutics Inc.

      DEF 14A - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

      4/8/25 4:15:04 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-1 filed by Actuate Therapeutics Inc.

      S-1 - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

      3/28/25 6:23:28 AM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actuate Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

      3/28/25 6:00:12 AM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Actuate Therapeutics Inc.

      10-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

      3/13/25 4:30:23 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actuate Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

      2/7/25 4:30:26 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Actuate Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Actuate Therapeutics Inc.

      SC 13D - ACTUATE THERAPEUTICS, INC. (0001652935) (Subject)

      8/19/24 8:59:59 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Actuate Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting

      Fireside discussion to explore clinical impact of the topline Phase 2 data in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) to be presented at ASCOIn-person event and virtual webcast to be held on Saturday, May 31, 2025, at 6:30 pm CDT CHICAGO and FORT WORTH, Texas, May 07, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that it will host an in-person key opinion leader (KOL) event, during the 2025 American

      5/7/25 8:00:00 AM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer

      Topline data shows statistically significant improvement in overall survival in elraglusib plus GnP combination arm versus GnP control armElraglusib/GnP combination arm demonstrated substantial improvement in median overall survival since the last data analysisClinical trial meets primary endpoint for overall survival and confirms significant 1-year survival rateElraglusib/GnP combination arm demonstrated a favorable risk-benefit profileTopline dataset to be presented in an oral presentation at the upcoming ASCO Annual Meeting Company plans to work with regulators to expeditiously bring elraglusib to commercialization CHICAGO and FORT WORTH, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Actua

      5/6/25 8:00:00 AM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025

      CHICAGO and FORT WORTH, Texas, April 30, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Daniel Schmitt, President & Chief Executive Officer of Actuate will present at the Citizens Life Sciences Conference 2025 taking place May 7-8 in New York, NY. Citizens JMP Life Sciences Conference Presentation Date:Thursday, May 8, 2025Time:12:30 PM ETWebcast Link:click here   The webcast of the presentation will be accessib

      4/30/25 8:00:00 AM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

      - Oral presentation at ASCO to highlight topline Phase 2 data of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) CHICAGO and FORT WORTH, Texas, April 23, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that topline clinical data from the randomized Phase 2 study (Actuate-1801 Part 3B) evaluating elraglusib have been selected for or

      4/23/25 10:24:10 AM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

      CHICAGO and FORT WORTH, Texas, April 17, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that data on elraglusib in advanced salivary gland carcinoma will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2025 taking place from April 25th – 30th at McCormick Place Convention Center, Chicago, IL. The abstracts will be published in the online Proceedings of the AACR. Poster

      4/17/25 8:00:00 AM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

      HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025. LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential. Successfully dosed multiple pati

      3/27/25 4:01:00 PM ET
      $ACTU
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer

      Initial Data from this Phase 2 Trial Demonstrates Early Evidence of Clinical Activity of Elraglusib (9-ING-41) in Combination with FOLFIRINOX and Losartan in Untreated Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)The Final Results from the Trial are Anticipated in 2026 CHICAGO and FORT WORTH, Texas, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), announced the completion of patient enrollment in the ongoing Phase 2 trial of F

      2/25/25 8:00:00 AM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actuate Therapeutics to Participate in Upcoming Investor Conferences in February

      CHICAGO and FORT WORTH, Texas, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Daniel Schmitt, President & Chief Executive Officer of Actuate will participate in the following upcoming investor conferences: BIO CEO & Investor ConferenceFormat: "IPO Class of 2024 Panel" and one-on-one meetingsDate: February 10, 2025Location: New York, NY Registered conference attendees may schedule one-on-one meetings with Actua

      2/6/25 8:00:00 AM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer

      CHICAGO and FORT WORTH, Texas, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to elraglusib, a novel GSK-3β inhibitor, for the treatment of pancreatic ductal adenocarcinoma (PDAC). "With limited treatment options available for patients with PDAC, the EMA Orphan Drug Designation and FDA Orphan Drug Designation granted t

      1/7/25 8:00:00 AM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

      Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall SurvivalDoubling of 1 Year Survival Rate and 37% Reduction in Risk of Death Two Month (29%) Increase in Median Overall SurvivalMultiple Patients with Complete Responses (CRs) and/or Partial Response (PR) with 100% Reduction in Target LesionsElraglusib in Combination with GnP Demonstrated a Favorable Risk-Benefit ProfileTrial Continues with Topline Data Anticipated in 1H 2025 CHICAGO and FORT WORTH, Texas, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treat

      12/17/24 8:00:00 AM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Actuate Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by President, CEO and Director Schmitt Daniel M

      4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

      4/2/25 1:44:57 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Mazar Andrew Paul

      4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

      4/2/25 1:43:25 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Lytle Paul J

      4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

      4/2/25 1:41:10 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Bios Equity Cof, Lp sold $199,992 worth of shares (24,999 units at $8.00) (SEC Form 4)

      4/A - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

      8/20/24 8:46:56 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Fletcher Aaron G.L. sold $199,992 worth of shares (24,999 units at $8.00) (SEC Form 4)

      4/A - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

      8/20/24 8:46:04 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Large owner Kreis Leslie W. sold $199,992 worth of shares (24,999 units at $8.00) (SEC Form 4)

      4/A - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

      8/20/24 8:45:30 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 16.4% Owner Thomson Todd S converted options into 2,577,312 shares, exercised 28,464 in-the-money shares at a strike of $5.27 and sold $150,000 worth of shares (18,750 units at $8.00) (SEC Form 4)

      4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

      8/16/24 9:12:15 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Bios Equity Cof, Lp

      4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

      8/14/24 8:56:46 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bios Equity Cof, Lp bought $4,000,000 worth of shares (500,000 units at $8.00), exercised 37,951 in-the-money shares at a strike of $5.27, sold $224,991 worth of shares (24,999 units at $9.00) and converted options into 9,380,699 shares (SEC Form 4)

      4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

      8/14/24 8:54:46 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Fletcher Aaron G.L.

      4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

      8/14/24 8:51:49 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Actuate Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bios Equity Cof, Lp bought $4,000,000 worth of shares (500,000 units at $8.00), exercised 37,951 in-the-money shares at a strike of $5.27, sold $224,991 worth of shares (24,999 units at $9.00) and converted options into 9,380,699 shares (SEC Form 4)

      4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

      8/14/24 8:54:46 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Fletcher Aaron G.L. converted options into 9,380,699 shares, bought $4,000,000 worth of shares (500,000 units at $8.00), exercised 37,951 in-the-money shares at a strike of $5.27 and sold $224,991 worth of shares (24,999 units at $9.00) (SEC Form 4)

      4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

      8/14/24 8:49:12 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Kreis Leslie W. converted options into 9,380,699 shares, bought $4,000,000 worth of shares (500,000 units at $8.00), exercised 37,951 in-the-money shares at a strike of $5.27 and sold $224,991 worth of shares (24,999 units at $9.00) (SEC Form 4)

      4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

      8/14/24 8:44:04 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Actuate Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

      HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025. LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential. Successfully dosed multiple pati

      3/27/25 4:01:00 PM ET
      $ACTU
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care